QS Investors LLC trimmed its stake in Edwards Lifesciences Corp (NYSE:EW) by 18.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,792 shares of the medical research company’s stock after selling 11,595 shares during the period. QS Investors LLC’s holdings in Edwards Lifesciences were worth $8,087,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Lindbrook Capital LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at $27,000. Nelson Roberts Investment Advisors LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at $30,000. Laurel Wealth Advisors LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at $32,000. AlphaMark Advisors LLC boosted its position in Edwards Lifesciences by 281.8% during the fourth quarter. AlphaMark Advisors LLC now owns 210 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 155 shares during the last quarter. Finally, We Are One Seven LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at $33,000. Institutional investors and hedge funds own 83.29% of the company’s stock.
In related news, CEO Michael A. Mussallem sold 32,800 shares of the firm’s stock in a transaction dated Friday, December 21st. The shares were sold at an average price of $146.03, for a total value of $4,789,784.00. Following the transaction, the chief executive officer now owns 75,926 shares of the company’s stock, valued at approximately $11,087,473.78. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Larry L. Wood sold 6,716 shares of the firm’s stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $148.15, for a total transaction of $994,975.40. Following the completion of the transaction, the vice president now directly owns 122,366 shares in the company, valued at approximately $18,128,522.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 168,522 shares of company stock worth $26,990,579. 1.84% of the stock is owned by insiders.
A number of equities analysts have recently issued reports on the stock. Royal Bank of Canada increased their price objective on shares of Edwards Lifesciences to $175.00 and gave the stock an “outperform” rating in a research report on Thursday, December 6th. UBS Group increased their price objective on shares of Edwards Lifesciences from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Tuesday. Stifel Nicolaus reissued a “positive” rating on shares of Edwards Lifesciences in a research report on Thursday, December 6th. Raymond James increased their price objective on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the stock an “outperform” rating in a research report on Thursday, December 6th. Finally, Citigroup increased their price objective on shares of Edwards Lifesciences from $119.00 to $130.00 and gave the stock a “sell” rating in a research report on Monday, February 25th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $171.10.
Shares of NYSE EW opened at $180.00 on Friday. Edwards Lifesciences Corp has a fifty-two week low of $123.00 and a fifty-two week high of $178.69. The stock has a market capitalization of $36.45 billion, a P/E ratio of 38.30, a price-to-earnings-growth ratio of 2.26 and a beta of 0.90. The company has a current ratio of 2.61, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.17. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. The business had revenue of $977.70 million for the quarter, compared to analysts’ expectations of $973.72 million. During the same quarter last year, the firm earned $0.94 EPS. As a group, sell-side analysts expect that Edwards Lifesciences Corp will post 5.21 earnings per share for the current year.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Recommended Story: What is dollar cost averaging (DCA)?
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.